AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19571762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined superficial and deep cervical plexus block (14 ml superficial + 4 ml deep of 0.25% bupivacaine)
Number of subjects: 90
Study 17268410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/day inulin
Number of subjects: 30
Study 17268410 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day inulin
Number of subjects: 30
Study 17268410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 8 g/day)
Number of subjects: 30
Study 16888425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 12
Study 16888425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12716777 — intervention group
Group type: EXPERIMENTAL
Intervention: murabutide 7 mg/day on five consecutive days/week
Number of subjects: 42
Study 12716777 — intervention group
Group type: COMPARATOR
Intervention: Control (no murabutide)
Number of subjects: 42
Study 12716777 — intervention group
Group type: EXPERIMENTAL
Intervention: murabutide 7 mg/day
Number of subjects: 42
Study 10640054 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge with home health care (postoperative day 4)
Number of subjects: 0
Study 10640054 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge (a day or more later without home health care)
Number of subjects: 0
Study 7483792 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE vaccine on days 0 and 28
Number of subjects: 121
Study 7483792 — intervention group
Group type: COMPARATOR
Intervention: TBE vaccine plus TBE immunoglobulin on day 0 plus TBE vaccine on day 28
Number of subjects: 121
Study 1836920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine
Number of subjects: 108
Study 1836920 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 108
Study 6123342 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (12 micrograms/kg)
Number of subjects: 6
Study 6123342 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (not specified dosage)
Number of subjects: 6
Study 6123342 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 6
Study 31876967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training in the RNR model of offending behavior (n=36)
Number of subjects: 59
Study 31876967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (n=23)
Number of subjects: 59
Study 31362591 — intervention group
Group type: COMPARATOR
Intervention: Lowest-income sites (quintile 1)
Number of subjects: 27862
Study 28478732 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic DJ (Blackstar, Urotech)
Number of subjects: 60
Study 28478732 — intervention group
Group type: COMPARATOR
Intervention: Standard DJ
Number of subjects: 60
Study 28478732 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic DJ
Number of subjects: 60
Study 28478732 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopic DJ
Number of subjects: 60
Study 25262388 — intervention group
Group type: EXPERIMENTAL
Intervention: water of the 3 sulfates
Number of subjects: 50
Study 25262388 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 50
Study 23819698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg twice daily
Number of subjects: 414
Study 23819698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 414
Study 23819698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 21674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with warfarin
Number of subjects: 50
Study 21674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 50
Study 21674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels
Number of subjects: 50
Study 21674132 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents (aspirin or thienopyridine)
Number of subjects: 50
Study 21674132 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic INR range
Number of subjects: 50
Study 18095748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541
Study 18095748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 16154543 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group (12 police officers with PTSD)
Number of subjects: 24
Study 16154543 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 traumatized police officers without lifetime PTSD)
Number of subjects: 24
Study 12546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (hydrocortisone sodium succinate at 150 mg to 200 mg daily)
Number of subjects: 120
Study 12546741 — intervention group
Group type: COMPARATOR
Intervention: Conventional supporting treatment
Number of subjects: 120
Study 12546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (hydrocortisone sodium succinate)
Number of subjects: 120
Study 12546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 120
Study 10732889 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1462
Study 8883116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol treatment (0.25 micrograms twice daily)
Number of subjects: 46
Study 8883116 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 supplementation (500‐1000 units daily)
Number of subjects: 46
Study 1396893 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid intake until 4 weeks of age
Number of subjects: 100
Study 1396893 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid regimen used in the hospital
Number of subjects: 100
Study 3919550 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (8 to 12 mg orally)
Number of subjects: 48
Study 3919550 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (8 to 12 mg intravenously)
Number of subjects: 48
Study 3919550 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (12 mg)
Number of subjects: 48
Study 3919550 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (12 mg intravenously)
Number of subjects: 48
Study 3919550 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1.6 mg sublingually)
Number of subjects: 48
Study 3919550 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine and Nitroglycerin
Number of subjects: 48
Study 29397899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day sodium benzoate
Number of subjects: 60
Study 29397899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day sodium benzoate
Number of subjects: 60
Study 29397899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27659931 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-pH, low-GDP peritoneal dialysis solution (balance)
Number of subjects: 0
Study 27659931 — intervention group
Group type: COMPARATOR
Intervention: Conventional peritoneal dialysis fluid (cPDF)
Number of subjects: 0
Study 24104055 — intervention group
Group type: EXPERIMENTAL
Intervention: Liking for food at the end of a consumption experience
Number of subjects: 0
Study 24104055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigating the decrease in liking from repeated consumption
Number of subjects: 0
Study 22100003 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 48
Study 22100003 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid ureterolithotripsy
Number of subjects: 48
Study 22100003 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ureterolithotomy
Number of subjects: 48
Study 22100003 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48
Study 20844595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg s.c. every other week for 4 weeks
Number of subjects: 24
Study 20844595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20844595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 24
Study 18927988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 15917949 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25‐2.5 mg/day)
Number of subjects: 23
Study 15917949 — intervention group
Group type: COMPARATOR
Intervention: Mofetil mycophenolate (2 mg/day)
Number of subjects: 23
Study 12813615 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (EP)
Number of subjects: 160
Study 12813615 — intervention group
Group type: COMPARATOR
Intervention: Abciximab (AB)
Number of subjects: 160
Study 12584789 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangya Tongmai Recipe (JYTMR)
Number of subjects: 37
Study 12584789 — intervention group
Group type: COMPARATOR
Intervention: Captopril (Control)
Number of subjects: 37
Study 10511062 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin twice a day for 3 days, followed by 20 mg omeprazole
Number of subjects: 21
Study 10511062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7742773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sec maximal exercise test
Number of subjects: 7
Study 7742773 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 sec maximal exercise test
Number of subjects: 7
Study 7742773 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 sec maximal exercise test
Number of subjects: 7
Study 2225396 — intervention group
Group type: COMPARATOR
Intervention: Hancock 19-mm modified orifice (MO) valve
Number of subjects: 100
Study 2225396 — intervention group
Group type: COMPARATOR
Intervention: Hancock 21-mm valve
Number of subjects: 100
Study 2225396 — intervention group
Group type: COMPARATOR
Intervention: Hancock 23-mm MO valve
Number of subjects: 100
Study 2225396 — intervention group
Group type: COMPARATOR
Intervention: Hancock 19-mm MO valve
Number of subjects: 100
Study 2225396 — intervention group
Group type: COMPARATOR
Intervention: Hancock 21-mm MO valve
Number of subjects: 100
Study 7050036 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 62
Study 7050036 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (6 fraction technique)
Number of subjects: 62
Study 27993589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination travoprost 0.004%/timolol 0.5% (TTFC)
Number of subjects: 81
Study 27993589 — intervention group
Group type: COMPARATOR
Intervention: Separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM)
Number of subjects: 81
Study 25548798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes twice a week)
Number of subjects: 116
Study 25548798 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FTC capsules alone (Group A)
Number of subjects: 60
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FTC combined with 300 mg TDF tablets (Group B)
Number of subjects: 60
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FTC plus 300 mg TDF with a high-fat diet (Group C)
Number of subjects: 60
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC capsules (Group D)
Number of subjects: 60
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC combined with 300 mg TDF tablets (Group E)
Number of subjects: 60
Study 24802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC plus 300 mg TDF with a high-fat diet (Group F)
Number of subjects: 60
Study 23010779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diets (40% fat, 15% protein)
Number of subjects: 811
Study 23010779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diets (15% fat, 25% protein)
Number of subjects: 811
Study 23010779 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorically restricted diets (various macronutrient compositions)
Number of subjects: 811
Study 23010779 — intervention group
Group type: EXPERIMENTAL
Intervention: All four dietary conditions
Number of subjects: 811
Study 23010779 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 811
Study 18706856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Disturbance Scale for Children (SDSC)
Number of subjects: 100
Study 18091269 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 596
Study 18091269 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 596
Study 15141265 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 59
Study 15141265 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 59
Study 11964938 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects models
Number of subjects: 0
Study 11964938 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with steeper marker drops
Number of subjects: 0
Study 9738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 531
Study 9738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 531
Study 9738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 531
Study 9738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Number of subjects: 531
Study 8291819 — intervention group
Group type: COMPARATOR
Intervention: Continuous Ambulatory Peritoneal Dialysis with a Y-connector
Number of subjects: 82
Study 8291819 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Cyclic Peritoneal Dialysis
Number of subjects: 82
Study 2544640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mg/ml)
Number of subjects: 71
Study 2544640 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (20 mg/ml)
Number of subjects: 71
Study 29470950 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 916
Study 29470950 — intervention group
Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC) - randomized
Number of subjects: 916
Study 29470950 — intervention group
Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC) - preference
Number of subjects: 916
Study 29470950 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC) - randomized
Number of subjects: 916
Study 27431644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20770
Study 24561962 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.5DS for both eyes
Number of subjects: 108
Study 24561962 — intervention group
Group type: EXPERIMENTAL
Intervention: Full correction for hyperopes
Number of subjects: 108
Study 24561962 — intervention group
Group type: COMPARATOR
Intervention: No glasses for hyperopes
Number of subjects: 108
Study 24561962 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles for myopes
Number of subjects: 108
Study 22281826 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Number of subjects: 122
Study 22281826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib (Macugen)
Number of subjects: 122
Study 22281826 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 122
Study 20819550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin ophthalmic gel
Number of subjects: 96
Study 20819550 — intervention group
Group type: COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Number of subjects: 96
Study 20819550 — intervention group
Group type: COMPARATOR
Intervention: Comparison of gatifloxacin ophthalmic gel vs solution
Number of subjects: 96
Study 18649049 — intervention group
Group type: COMPARATOR
Intervention: Myocrisin
Number of subjects: 58
Study 18649049 — intervention group
Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 58
Study 17130189 — intervention group
Group type: EXPERIMENTAL
Intervention: Community center-based resistance training maintenance program (2 times/week for 12 months)
Number of subjects: 57
Study 17130189 — intervention group
Group type: COMPARATOR
Intervention: Home-based resistance training maintenance program (2 times/week for 12 months)
Number of subjects: 57
Study 12795036 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention (individualized goal setting)
Number of subjects: 57
Study 10748311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 18
Study 10748311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9352758 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.0625% + fentanyl 3.3 micrograms/ml infusion (Group EPI)
Number of subjects: 120
Study 9352758 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine analgesia (Group PCA)
Number of subjects: 120
Study 8403900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield IUD
Number of subjects: 0
Study 8403900 — intervention group
Group type: COMPARATOR
Intervention: Lippes Loop D or Copper IUDs
Number of subjects: 0
Study 3536108 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 13
Study 3536108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine eight hourly for three weeks
Number of subjects: 13
Study 3536108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3142949 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 34
Study 3142949 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 34
Study 30073793 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat IR 40 mg
Number of subjects: 1790
Study 30073793 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat IR 80 mg
Number of subjects: 1790
Study 30073793 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat XR 40 mg
Number of subjects: 1790
Study 30073793 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat XR 80 mg
Number of subjects: 1790
Study 30073793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790
Study 28655620 — intervention group
Group type: EXPERIMENTAL
Intervention: Resealable package
Number of subjects: 0
Study 28655620 — intervention group
Group type: COMPARATOR
Intervention: Unresealable package
Number of subjects: 0
Study 26210304 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous defocused CO2 laser treatment
Number of subjects: 171
Study 26210304 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic conservative treatment (oral salve containing lidocaine hydrochloride or systemic diclofenac)
Number of subjects: 171
Study 23041585 — intervention group
Group type: COMPARATOR
Intervention: Flat dosing of carboplatin (Arm A)
Number of subjects: 964
Study 23041585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapatient dose escalation of carboplatin (Arm B)
Number of subjects: 964
Study 21601973 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 33
Study 19458031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol esters (2.5 g/d)
Number of subjects: 0
Study 19458031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (2.5 g/d)
Number of subjects: 0
Study 19458031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16924445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector‐Vision navigation system (n=60)
Number of subjects: 120
Study 16924445 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (n=60)
Number of subjects: 120
Study 12417984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laserneedle stimulation
Number of subjects: 27
Study 12417984 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual needle stimulation
Number of subjects: 27
Study 10560752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 7738618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy with megestrol acetate
Number of subjects: 300
Study 7738618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy with fadrozole
Number of subjects: 300
Study 7738618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum c-erbB-2 levels
Number of subjects: 300
Study 7738618 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum c-erbB-2 levels
Number of subjects: 300
Study 1855082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF)
Number of subjects: 0
Study 1855082 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 1855082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF) in patients with marrow graft failure
Number of subjects: 0
Study 1855082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF) in pediatric patients
Number of subjects: 0
Study 7323140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) at four different doses
Number of subjects: 10
Study 31543299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-diode laser treatment (PTT group)
Number of subjects: 22
Study 31543299 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PTT teeth)
Number of subjects: 22
Study 30390647 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mass drug administration (MDA) consisting of 3 rounds of a 3-day course of dihydroartemisinin-piperaquine plus a single low dose of primaquine.
Number of subjects: 1919
Study 30390647 — intervention group
Group type: COMPARATOR
Intervention: Deferred mass drug administration (control group).
Number of subjects: 1919
Study 30390647 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of 3 rounds of MDA.
Number of subjects: 1919
Study 30390647 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mass drug administration (MDA).
Number of subjects: 1919